Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
Cell Stem Cell
|
October 8, 2013
HIF-2α protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress
Kevin Rouault-Pierre, Lourdes Lopez-Onieva, Katie Foster, et al.
Blood
|
July 1, 2011
Differential and tumor-specific expression of CD160 in B-cell malignancies
Timothy W Farren, Jerome Giustiniani, Feng-Ting Liu, et al.
Nucleic Acids Research
|
December 8, 2017
Improving CRISPR-Cas specificity with chemical modifications in single-guide RNAs
Daniel E Ryan, David Taussig, Israel Steinfeld, et al.
Biochemistry
|
April 18, 2022
Phosphonoacetate Modifications Enhance the Stability and Editing Yields of Guide RNAs for Cas9 Editors
Daniel E Ryan, Tamar Diamant-Levi, Israel Steinfeld, et al.
British Journal of Haematology
|
July 8, 2024
CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK
Priyanka Mehta, Victoria Campbell, Jamie Maddox, et al.
British Journal of Haematology
|
March 11, 2024
Capture-based targeted sequencing using a T-cell control in myeloid malignancies and idiopathic cytopenias
Grzegorz Pietka, Corinne De Lord, Gwynn Matthias, et al.
Blood Advances
|
April 12, 2022
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
Marina Y Konopleva, Christoph Röllig, Jamie Cavenagh, et al.
The Lancet. Haematology
|
March 31, 2022
Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial
David I Marks, Amy A Kirkwood, Clare J Rowntree, et al.
Blood Advances
|
September 12, 2024
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy
Jad Othman, Angela Hwang, Maximillian Brodermann, et al.
Blood Advances
|
December 1, 2023
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML
Carlos Jimenez-Chillon, Jad Othman, David Taussig, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
Cell Stem Cell
|
October 8, 2013
HIF-2α protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress
Kevin Rouault-Pierre, Lourdes Lopez-Onieva, Katie Foster, et al.
Blood
|
July 1, 2011
Differential and tumor-specific expression of CD160 in B-cell malignancies
Timothy W Farren, Jerome Giustiniani, Feng-Ting Liu, et al.
Nucleic Acids Research
|
December 8, 2017
Improving CRISPR-Cas specificity with chemical modifications in single-guide RNAs
Daniel E Ryan, David Taussig, Israel Steinfeld, et al.
Biochemistry
|
April 18, 2022
Phosphonoacetate Modifications Enhance the Stability and Editing Yields of Guide RNAs for Cas9 Editors
Daniel E Ryan, Tamar Diamant-Levi, Israel Steinfeld, et al.
British Journal of Haematology
|
July 8, 2024
CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK
Priyanka Mehta, Victoria Campbell, Jamie Maddox, et al.
British Journal of Haematology
|
March 11, 2024
Capture-based targeted sequencing using a T-cell control in myeloid malignancies and idiopathic cytopenias
Grzegorz Pietka, Corinne De Lord, Gwynn Matthias, et al.
Blood Advances
|
April 12, 2022
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
Marina Y Konopleva, Christoph Röllig, Jamie Cavenagh, et al.
The Lancet. Haematology
|
March 31, 2022
Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial
David I Marks, Amy A Kirkwood, Clare J Rowntree, et al.
Blood Advances
|
September 12, 2024
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy
Jad Othman, Angela Hwang, Maximillian Brodermann, et al.
Blood Advances
|
December 1, 2023
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML
Carlos Jimenez-Chillon, Jad Othman, David Taussig, et al.
Page
of 5